The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders

Sindher, Sayantani; Barshow, Suzanne; Tirumalasetty, Jyothi; Arasi, Stefania; Atkins, Dan; Bauer, Maureen; Bégin, Philippe; Collins, Margaret H.; Deschildre, A.; Doyle, Alfred D.; Fiocchi, Alessandro; Furuta, Glenn T.; Garcia-Lloret, M.; Mennini, Maurizio; Rothenberg, Marc E.; Spergel, Jonathan M.; Wang, Julie; Wood, Robert A.; Wright, Benjamin L.; Zuberbier, Torsten; Chin, Andrew R.; Long, Andrew J.; Nadeau, Kari; Chinthrajah, R. Sharon

doi:10.1016/j.jaci.2023.01.007

Cited by 18 publications

(11 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, a substantial percentage (43-86%) of FA-afflicted children globally exhibit allergies to multiple foods, making sequential OIT for various allergens burdensome for both patients and families [18][19][20][21]. As a result, there is a growing demand for more effective innovative therapeutics [22]. The emergence of biologic drugs, such as omalizumab, dupilumab, and tezepelumab, shows promise in addressing a range of allergic conditions, including asthma, urticaria, eosinophilic esophagitis (EoE), atopic dermatitis (AD), nasal polyposis, and FA [23][24][25][26][27][28].…”

Section: Andandmentioning

confidence: 99%

“…As a result, there is a growing demand for more effective innovative therapeutics [22]. The emergence of biologic drugs, such as omalizumab, dupilumab, and tezepelumab, shows promise in addressing a range of allergic conditions, including asthma, urticaria, eosinophilic esophagitis (EoE), atopic dermatitis (AD), nasal polyposis, and FA [23][24][25][26][27][28]. In contrast to OIT's allergen-specific focus, biologics target fundamental mechanistic pathways driving allergic reactions, including immunoglobulin E (IgE), interleukin (IL)-4 and IL-13, and alarmin pathways (TSLP, IL-33, and IL-25) [28].…”

Section: Andandmentioning

confidence: 99%

“…The emergence of biologic drugs, such as omalizumab, dupilumab, and tezepelumab, shows promise in addressing a range of allergic conditions, including asthma, urticaria, eosinophilic esophagitis (EoE), atopic dermatitis (AD), nasal polyposis, and FA [23][24][25][26][27][28]. In contrast to OIT's allergen-specific focus, biologics target fundamental mechanistic pathways driving allergic reactions, including immunoglobulin E (IgE), interleukin (IL)-4 and IL-13, and alarmin pathways (TSLP, IL-33, and IL-25) [28]. This antigen-agnostic approach positions biologics to potentially mitigate or nullify allergic reactions triggered by food, as indicated by their inclusion in numerous ongoing clinical trials [22].…”

Section: Andandmentioning

confidence: 99%

“…In contrast to OIT's allergen-specific focus, biologics target fundamental mechanistic pathways driving allergic reactions, including immunoglobulin E (IgE), interleukin (IL)-4 and IL-13, and alarmin pathways (TSLP, IL-33, and IL-25) [28]. This antigen-agnostic approach positions biologics to potentially mitigate or nullify allergic reactions triggered by food, as indicated by their inclusion in numerous ongoing clinical trials [22]. This review provides an overview of biologics studied in FA, emphasizing their integration into clinical practice and potential advantages over other therapeutic strategies like OIT.…”

Section: Andandmentioning

confidence: 99%

See 3 more Smart Citations

Role of biologics in severe food allergy

Dinardo,

Cafarotti,

Fierro

et al. 2024

Current Opinion in Allergy &Amp; Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Purpose of review This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities. Recent findings This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management. Recent studies and clinical trials highlight the impact of anti-IgE treatment on food allergies, revealing critical findings such as dose-related efficacy, facilitation of rapid desensitization in peanut allergies, and the sustained positive outcomes observed in individuals with multifood allergies. Summary The use of biologics presents a groundbreaking approach in the treatment of food allergies. The multifaceted action of these agents, along with their potential to overcome the challenges associated with traditional therapies, marks a significant advancement. Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.

show abstract

Section: Andandmentioning

confidence: 99%

Section: Andandmentioning

confidence: 99%

Section: Andandmentioning

confidence: 99%

Section: Andandmentioning

confidence: 99%

See 2 more Smart Citations

Role of biologics in severe food allergy

Dinardo,

Cafarotti,

Fierro

et al. 2024

Current Opinion in Allergy &Amp; Clinical Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Biological treatment may also be an opportunity to treat severe cases in children. Clinical trials are underway in people under 18 on mepolizumab, dupilumab, lirentelimab (anti-Siglec-8 therapy), or benralizumab (anti-IL-5Ra) [ 108 ]. Table 3 presents different recommendations and international consensus in the treatment of children with EoE.…”

Section: Eoe Differences In Pediatric and Adolescent Patientsmentioning

confidence: 99%

Eosinophilic Esophagitis—What Do We Know So Far?

Wąsik

Małecka-Wojciesko

2023

JCM

View full text Add to dashboard Cite

Eosinophilic esophagitis is a Th-2 antigen-mediated disease in which there is an influx of eosinophils to all layers of the esophagus, triggering an inflammatory response. Chronic inflammatory process causes esophageal remodeling, leading to difficulties in swallowing. Food impaction, heartburn, and chest pain are other characteristic (but not pathognomonic) symptoms in adults. Although the disease has only been described since in the early 1970s, its incidence and prevalence are rapidly growing, especially in Western countries. According to the diagnostic guidelines, there should be at least 15 eosinophils visible per high-power field in biopsies obtained from different sites in the esophagus upon endoscopy with relevant esophageal symptoms. Other diseases that can cause esophageal eosinophilia should be ruled out. Eosinophilic esophagitis treatment may be challenging; however, new methods of management have recently emerged. The currently used proton pump inhibitors, topical corticosteroids, and elimination diet are combined with biological treatment. New methods for disease diagnostics and clinical course assessment are also available. This review presents current knowledge about the disease, supported by the latest research data.

show abstract